Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Axsome Therapeutics has delivered a very large 5 year return while the current valuation checks point to a stock that now looks closer to fairly priced than clearly cheap. The market has rewarded the story, so the question is whether the present price still leaves enough room for longer term investors to be comfortable.
-
Axsome Therapeutics has returned about 9.4x over the past 5 years, which puts the recent share price firmly at the higher end of its historical range for many holders.
-
Expectations around Axsome Therapeutics turning its pipeline into durable revenue and cash flow can support the current price, while execution risk on clinical, regulatory or commercialization efforts may limit how much investors are willing to pay from here.
-
The valuation checks give Axsome Therapeutics a mixed read, with a 4 out of 6 score that suggests neither a clear bargain nor an obvious overvaluation.
The issue now is whether Axsome Therapeutics' recent share price strength still lines up with what investors receive in terms of business progress and risk.
Does Axsome Therapeutics Look Fairly Valued on Sales?
For a company like Axsome Therapeutics that is working to build scale on existing products, the P/S ratio is a straightforward way to think about what investors are paying for each dollar of current revenue.
Axsome Therapeutics trades on a P/S of about 16.0x, well above the wider pharmaceuticals industry average of roughly 4.9x and also above the peer group average of about 9.7x. A tailored fair P/S ratio for the stock sits close to 16.3x. This suggests that the current premium to the sector is largely in line with what might be expected given Axsome Therapeutics' profile and risk mix.
The gap between the current 16.0x and the modelled fair 16.3x is small. As a result, the market multiple does not point to a clear bargain or an obvious excess at today's price. For investors who use comparables, Axsome Therapeutics looks to be priced broadly in line with what this framework suggests.
On the P/S multiple, Axsome Therapeutics stock comes across as roughly fairly valued.
See what the numbers say about this price — find out in our valuation breakdown.
The Axsome Therapeutics Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Axsome Therapeutics pick up where the valuation checks stop and explain what kind of future would need to play out for the stock to be worth materially more or materially less than today's price on the Community page. Each one links its number to a specific view on how Axsome Therapeutics' growth, margins and risks might develop, which you can test against new information over time.
One of the top community narratives on Axsome Therapeutics: 22% undervalued
"Axsome's portfolio is expanding with the launch of SYMBRAVO for migraine and ongoing robust growth of Auvelity and Sunosi, reflecting increased societal prioritization of mental health and CNS disorders..."
Read one of the top narratives on Axsome Therapeutics
Do you think there's more to the story for Axsome Therapeutics? Head over to our Community to see what others are saying!
The Bottom Line
Axsome Therapeutics now screens as about right on market multiples, rather than clearly cheap. That means the easy part of the re-rating looks done and future returns are more likely to track how the business delivers against current expectations. The key question from here is whether Axsome Therapeutics can turn its existing portfolio and pipeline into durable revenue and cash flow at a level that justifies holding this richer P/S, or whether any slip in execution or sentiment forces the multiple to reset.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AXSM .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
